-
公开(公告)号：US20140378387A1
公开(公告)日：2014-12-25
申请号：US14370515
申请日：2013-01-04
Applicant: Centre for Addiction and Mental Health
Inventor： Fang Liu
IPC: C07K14/705
CPC classification number: C07K14/70571 , A61K38/00 , C07K2319/00 , C07K2319/10 , C07K2319/23
Abstract: Disclosed are polypeptides, compositions and methods for the treatment or prophylaxis of multiple sclerosis. The method involves the steps of administering a polypeptide, or nucleic acid encoding the polypeptide, comprising the GluR2 NTa1-3-2 (Y142-K172) amino acid sequence as shown by SEQ ID NO:1 or SEQ ID NO:5 to a subject in need of the treatment.
Abstract translation: 公开了用于治疗或预防多发性硬化的多肽，组合物和方法。 该方法包括将如SEQ ID NO：1或SEQ ID NO：5所示的GluR2 NTa1-3-2（Y142-K172）氨基酸序列的多肽或编码该多肽的核酸给予受试者的步骤 需要治疗。
-
公开(公告)号：US20220185813A1
公开(公告)日：2022-06-16
申请号：US17310996
申请日：2020-03-05
Applicant: Centre for Addiction and Mental Health , The University Court of the University of Aberdeen
Inventor： Fang Liu , lain Greig , Dongxu Zhai , Stephen Allan Smith , Chiara Zanato , Chih-Chung Tseng
IPC: C07D487/04 , A61P25/00
Abstract: The present disclosure relates to compounds of the Formula (I) which have shown utility in modulating AMPA receptor signaling and thus preventing AMPA receptor-mediated toxicity, which may find use in the treatment of diseases in which AMPA receptor activation plays a role in neurodegeneration, including the treatment of multiple sclerosis and other diseases.
-
Patent Agency Ranking
公开(公告)号：US09708385B2
公开(公告)日：2017-07-18
申请号：US14996354
申请日：2016-01-15
Applicant: Centre for Addiction and Mental Health
IPC: C07K14/705 , C07K14/47 , C07K16/28 , A61K38/00
CPC classification number: C07K14/70571 , A61K38/00 , C07K14/47 , C07K16/286 , C07K2319/10
Abstract: The present invention provides for prevention and/or treatment of neurological or neuropsychiatric disorders involving abnormal D1-D2 dopamine receptor coupling and/or activation. Methods and agents are provided for modulating dopamine receptor function arising from D1-D2 coupling and/or activation. Agents of the present invention include fragments of D2 receptor or D1 receptor that can disrupt D1-D2 coupling.
-
公开(公告)号：US09518104B2
公开(公告)日：2016-12-13
申请号：US14370515
申请日：2013-01-04
Applicant: Centre for Addiction and Mental Health
Inventor： Fang Liu
IPC: C07K14/705 , A61K38/00
CPC classification number: C07K14/70571 , A61K38/00 , C07K2319/00 , C07K2319/10 , C07K2319/23
Abstract: Disclosed are polypeptides, compositions and methods for the treatment or prophylaxis of multiple sclerosis. The method involves the steps of administering a polypeptide, or nucleic acid encoding the polypeptide, comprising the GluR2 NTal-3-2 (Y142-K172) amino acid sequence as shown by SEQ ID NO:1 or SEQ ID NO:5 to a subject in need of the treatment.
Abstract translation: 公开了用于治疗或预防多发性硬化的多肽，组合物和方法。 该方法包括以下步骤：将如SEQ ID NO：1或SEQ ID NO：5所示的包含GluR2 NTal-3-2（Y142-K172）氨基酸序列的多肽或编码该多肽的核酸给予受试者 需要治疗。
-
5.发明申请Polypeptides and Methods For Modulating D1-D2 Dopamine Receptor Interaction and Function 审中-公开多肽和调节D1-D2多巴胺受体相互作用和功能的方法公开(公告)号：US20160237138A1
公开(公告)日：2016-08-18
申请号：US14996354
申请日：2016-01-15
Applicant: Centre for Addiction and Mental Health
IPC: C07K14/705
CPC classification number: C07K14/70571 , A61K38/00 , C07K14/47 , C07K16/286 , C07K2319/10
Abstract: The present invention provides for prevention and/or treatment of neurological or neuropsychiatric disorders involving abnormal D1-D2 dopamine receptor coupling and/or activation. Methods and agents are provided for modulating dopamine receptor function arising from D1-D2 coupling and/or activation. Agents of the present invention include fragments of D2 receptor or D1 receptor that can disrupt D1-D2 coupling.
Abstract translation: 本发明提供预防和/或治疗涉及D1-D2多巴胺受体偶联和/或活化异常的神经或神经精神障碍。 提供了用于调节由D1-D2偶联和/或激活产生的多巴胺受体功能的方法和试剂。 本发明的药剂包括可以破坏D1-D2偶联的D2受体或D1受体的片段。
-
6.发明授权公开(公告)号：US09266954B2
公开(公告)日：2016-02-23
申请号：US13862010
申请日：2013-04-12
Applicant: Centre for Addiction and Mental Health
IPC: C07K16/28 , C07K14/705 , C07K14/47 , A61K38/00
CPC classification number: C07K14/70571 , A61K38/00 , C07K14/47 , C07K16/286 , C07K2319/10
Abstract: The present invention provides for prevention and/or treatment of neurological or neuropsychiatric disorders involving abnormal D1-D2 dopamine receptor coupling and/or activation. Methods and agents are provided for modulating dopamine receptor function arising from D1-D2 coupling and/or activation. Agents of the present invention include fragments of D2 receptor or D1 receptor that can disrupt D1-D2 coupling.
Abstract translation: 本发明提供预防和/或治疗涉及D1-D2多巴胺受体偶联和/或活化异常的神经或神经精神障碍。 提供了用于调节由D1-D2偶联和/或激活产生的多巴胺受体功能的方法和试剂。 本发明的药剂包括可以破坏D1-D2偶联的D2受体或D1受体的片段。
-
公开(公告)号：US08552152B2
公开(公告)日：2013-10-08
申请号：US13645780
申请日：2012-10-05
Applicant: Centre for Addiction and Mental Health
Inventor： Fang Liu
CPC classification number: C07K14/001 , A61K31/7088 , C07K14/705 , G01N33/9413 , G01N2800/044 , G01N2800/2835 , G01N2800/2864 , G01N2800/304
Abstract: The present invention provides for diagnosis or treatment of neurological or neuropsychiatric disorders involving abnormal dopamine neurotransmission. Methods and agents are provided for modulating dopamine transporter activity and modulating dopaminergic neurotransmission. Agents of the present invention include fragments of D2 receptor or dopamine transporter (DAT) that can disrupt D2-DAT coupling.
Abstract translation: 本发明提供诊断或治疗涉及异常多巴胺神经传递的神经或神经精神障碍。 提供了调节多巴胺转运蛋白活性和调节多巴胺能神经传递的方法和试剂。 本发明的试剂包括可破坏D2-DAT偶联的D2受体或多巴胺转运蛋白（DAT）的片段。
-
-
-
-
-
-
Search Results
7
records
(took 0.02 seconds)
